Lai Kai Pharmaceutical-B (02105): LAE103 completed the first patient administration in the Phase I single dose escalation study

Zhitong Finance App News, Lai Kai Pharmaceutical-B (02105) announced that the Group has initiated the enrollment of subjects for LAE103 (a self-developed ActRIIb monoclonal antibody) Phase I single dose escalation study (SAD study) in Australia. As of the date of this announcement, the first test subject had completed administration.

The SAD study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic properties of LAE103 (subcutaneous injection) in healthy overweight or obese subjects. The Group aims to release the top line data for this SAD study in the third quarter of 2026.

The Group strives to introduce this precision therapy into cardiovascular and metabolic diseases where there are major unmet medical needs, such as obesity, muscle weakness, and heart failure.